Droperidol

Base Information

• Chemical Name: Droperidol
• CAS No.: 548-73-2
• Molecular Formula: C22H22FN3O2
• Molecular Weight: 379.434
• Hs Code.: 2933995800
• European Community (EC) Number: 208-957-8
• NSC Number: 757819,169874
• UNII: O9U0F09D5X
• DSSTox Substance ID: DTXSID6022973
• Nikkaji Number: J26.622A
• Wikipedia: Droperidol
• Wikidata: Q174259
• NCI Thesaurus Code: C458
• RXCUI: 3648
• Pharos Ligand ID: SKWTUHL8J97Y
• Metabolomics Workbench ID: 42804
• ChEMBL ID: CHEMBL1108
• Mol file: 548-73-2.mol

Synonyms:Dehidrobenzperidol;Dehydrobenzperidol;Droleptan;Droperidol;Inapsine

Chemical Property of Droperidol

Chemical Property:

• Appearance/Colour: Pale yellow solid
• Melting Point: 148-149 °C
• Refractive Index: 1.613
• PKA: 7.64(at 25℃)
• PSA: 58.10000
• Density: 1.269 g/cm³
• LogP: 3.61630
• Storage Temp.: 2-8°C
• Solubility.: Practically insoluble in water, freely soluble in dimethylformamide and in methylene chloride, sparingly soluble in ethanol (96 per cent).
• Water Solubility.: 4.1mg/L(30 oC)
• XLogP3: 3.5
• Hydrogen Bond Donor Count: 1
• Hydrogen Bond Acceptor Count: 4
• Rotatable Bond Count: 6
• Exact Mass: 379.16960512
• Heavy Atom Count: 28
• Complexity: 615

Purity/Quality:

99% ^*data from raw suppliers

Droperidol ^*data from reagent suppliers

Safty Information:

• Pictogram(s): Xn
• Hazard Codes: Xn
• Statements: 22
• Safety Statements: 36

MSDS Files:

SDS file from LookChem

Total 1 MSDS from other Authors

Useful:

• Canonical SMILES: C1CN(CC=C1N2C3=CC=CC=C3NC2=O)CCCC(=O)C4=CC=C(C=C4)F
• Recent ClinicalTrials: Low-dose Droperidol for Prevention of Postoperative Delirium in Elderly Patients After Non-cardiac Surgery
• Recent EU Clinical Trials: à compléter
• Recent NIPH Clinical Trials: Efficacy of pentazocine on pruritus during cesarean section due to spinal anesthesia-added opioids.
• Description: D roperidol is a butyrophenone that has potent antidopaminergic (D2) activity and mild α2-blocking actions. It produces sedation and anxiolysis and is an effective antiemetic. A dverse effects include vasodilatation and hypotension, and at higher doses, dystonic reactions can occur. D roperidol was used for premedication and in neuroleptanaesthesia until reports of death from long QT syndrome led to its withdrawal in 2001. It has recently been reintroduced and licenced at lower doses for prevention of postoperative nausea and vomiting. D roperidol has an onset of 3–10 min after i.v. injection and duration of action of 6–12h. It undergoes hepatic metabolism, but approximately 10% of the drug is excreted unchanged in the urine.
• Uses: A D1, D2 dopamine receptor antagonist; butyrophenone antipsychotic and anti-emetic. H2 antihistamine A D1DR and D2DR inhibitor. The neuroleptic droperidol possesses antipsychotic, sedative, and antishock action. It potentiates the action of drugs for narcosis. In psychiatric practice, droperidol is used for psychomotor excitement and hallucinations. The principal use of this drug lies in anesthesiology for neuroleptanalgesia in combination with fentanyl. It is used in premedication as well as in surgical operations and post-operational circumstances.
• Therapeutic Function: Tranquilizer
• Clinical Use: #N/A
• Drug interactions: Potentially hazardous interactions with other drugsAnaesthetics: enhanced hypotensive effect; effects of thiopental enhanced.Analgesics: increased risk of ventricular arrhythmias with methadone; increased risk of convulsions with tramadol; enhanced hypotensive and sedative effects with opioids.Anti-arrhythmics increased risk of ventricular arrhythmias with anti-arrhythmics that prolong the QT interval, e.g. procainamide, disopyramide, dronedarone and amiodarone - avoid.Antibacterials: increased risk of ventricular arrhythmias with moxifloxacin and macrolides - avoid; increased risk of ventricular arrhythmias with delamanid.Antidepressants: increased risk of ventricular arrhythmias with fluoxetine, fluvoxamine, sertraline or tricyclics - avoid; possible increased risk of convulsions with vortioxetine.Antiepileptics: convulsive threshold lowered.Antimalarials: avoid with artemether/lumefantrine and piperaquine with artenimol; increased risk of ventricular arrhythmias with chloroquine, hydroxychloroquine or quinine - avoid.Antipsychotics: increased risk of ventricular arrhythmias with amisulpride, pimozide, sulpiride, phenothiazines that prolong QT interval or haloperidol - avoid; possibly increased risk of ventricular arrhythmias with risperidone.Antivirals: concentration possibly increased with ritonavirAnxiolytics and hypnotics: increased sedative effects.Atomoxetine: increased risk of ventricular arrhythmias.Beta-blockers: enhanced hypotensive effect; increased risk of ventricular arrhythmias with sotalol - avoid.Cytotoxics: increased risk of ventricular arrhythmias with arsenic trioxide and possibly ceritinib.Desferrioxamine: avoid concomitant use.Diuretics: enhanced hypotensive effect.Hormone antagonists: increased risk of ventricular arrhythmias with tamoxifen - avoid.Lithium: increased risk of extrapyramidal side effects and possibly neurotoxicity.Pentamidine: increased risk of ventricular arrhythmias - avoid.Tacrolimus: increased risk of ventricular arrhythmias - avoid.

Technology Process of Droperidol

There total 3 articles about Droperidol which guide to synthetic route it. The literature collected by LookChem mainly comes from the sharing of users and the free literature resources found by Internet computing technology. We keep the original model of the professional version of literature to make it easier and faster for users to retrieve and use. At the same time, we analyze and calculate the most feasible synthesis route with the highest yield for your reference as below:

synthetic route:

Reference yield:

1-(p-Fluorophenyl)-4-[4-(2-oxo-1-benzimidazolinyl)-1,2,3,6-tetrahydro-1-pyridyl]-1-butanol (60373-72-0) → droperidol (548-73-2)

Guidance literature:

In chloroform;

Reference yield:

C22H22FN3O2C2H4O → droperidol (548-73-2)

Guidance literature:

With hydrogenchloride; In methanol; for 1.5h;

DOI:10.1016/j.tet.2007.06.106

Reference yield:

→ droperidol (548-73-2)

Guidance literature:

upstream raw materials:

1-(p-Fluorophenyl)-4-[4-(2-oxo-1-benzimidazolinyl)-1,2,3,6-tetrahydro-1-pyridyl]-1-butanol

Refernces

• 1、 -. "Method for inducing crystalline state transition in medicinal substance". . . Retrieved 2008/06/13.